RESUMEN
Phosphodiesterase type 5 inhibitors (PDE5is) constitute the primary therapeutic option for treating erectile dysfunction (ED). Nevertheless, a substantial proportion of patients, approximately 30%, do not respond to PDE5i treatment. Therefore, new treatment methods are needed. In this study, we identified a pathway that contributes to male erectile function. We show that mechano-regulated YAP/TAZ signaling in smooth muscle cells (SMCs) upregulates adrenomedullin transcription, which relaxed the SMCs to maintain erection. Using single-nucleus RNA sequencing, we investigated how penile erection stretches the SMCs, inducing YAP/TAZ activity. Subsequently, we demonstrate that YAP/TAZ plays a role in erectile function and penile rehabilitation, using genetic lesions and various animal models. This mechanism relies on direct transcriptional regulation of adrenomedullin by YAP/TAZ, which in turn modulates penile smooth muscle contraction. Importantly, conventional PDE5i, which targets NO-cGMP signaling, does not promote erectile function in YAP/TAZ-deficient ED model mice. In contrast, by activating the YAP/TAZ-adrenomedullin cascade, mechanostimulation improves erectile function in PDE5i nonrespondent ED model rats and mice. Furthermore, using clinical retrospective observational data, we found that mechanostimulation significantly promotes erectile function in patients irrespective of PDE5i use. Our studies lay the groundwork for exploring the mechano-YAP/TAZ-adrenomedullin axis as a potential target in the treatment of ED.
Asunto(s)
Adrenomedulina , Disfunción Eréctil , Proteínas Coactivadoras Transcripcionales con Motivo de Unión a PDZ , Proteínas Señalizadoras YAP , Animales , Humanos , Masculino , Ratones , Ratas , Adrenomedulina/fisiología , Disfunción Eréctil/genética , Erección Peniana/fisiología , Pene , Estudios Retrospectivos , Proteínas Señalizadoras YAP/fisiología , Proteínas Coactivadoras Transcripcionales con Motivo de Unión a PDZ/fisiologíaRESUMEN
RATIONALE: Calcitonin gene-related peptide (CGRP) and its family members adrenomedullin (ADM) and adrenomedullin 2 (ADM2; also known as intermedin) support vascular adaptions in rat pregnancy. OBJECTIVE: This study aimed to assess the relaxation response of uterine artery (UA) for CGRP, ADM, and ADM2 in nonpregnant and pregnant women and identify the involved mechanisms. FINDINGS: (1) Segments of UA from nonpregnant women that were precontracted with U46619 (1µM) in vitro are insensitive to the hypotensive effects of CGRP, ADM, and ADM2; (2) CGRP, ADM, and ADM2 (0.1-100nM) dose dependently relax UA segments from pregnant women with efficacy for CGRPâ >â ADMâ =â ADM2; (3) the relaxation responses to CGRP, ADM, and ADM2 are differentially affected by the inhibitors of nitric oxide (NO) synthase (L-NAME), adenylyl cyclase (SQ22536), apamin, and charybdotoxin; (4) UA smooth muscle cells (UASMC) express mRNA for calcitonin receptor-like receptor (CRLR) and receptor activity modifying protein (RAMP)1 and RAMP2 but not RAMP3; (5) receptor heterodimer comprising CRLR/RAMP1 and CRLR/RAMP2 but not CRLR/RAMP3 is present in UA; (6) soluble fms-like tyrosine kinase (sFLT-1) and TNF-α treatment decrease the expression of RAMP1 mRNA (Pâ <â 0.05) in UASMC; and (7) sFLT-1 treatment impairs the association of CRLR with all 3 peptides while TNF-α inhibits the interaction of CGRP but not ADM or ADM2 with CRLR in UASMC (Pâ <â 0.05). CONCLUSIONS: Relaxation sensitivity of UA for CGRP, ADM, and ADM2 is increased during pregnancy via peptide-specific involvement of NO system and endothelium-derived hyperpolarizing factors; vascular disruptors such as sFLT-1 and TNFα adversely impact their receptor system in UASMC.
Asunto(s)
Adrenomedulina/fisiología , Hormonas Peptídicas/fisiología , Arteria Uterina/metabolismo , Ácido 15-Hidroxi-11 alfa,9 alfa-(epoximetano)prosta-5,13-dienoico/farmacología , Apamina , Caribdotoxina , Dimerización , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Técnicas In Vitro , Proteínas de la Membrana/metabolismo , Miocitos del Músculo Liso/metabolismo , Embarazo , ARN Mensajero/metabolismo , Proteína 1 Modificadora de la Actividad de Receptores/metabolismo , Proteína 2 Modificadora de la Actividad de Receptores/metabolismo , Proteína 3 Modificadora de la Actividad de Receptores/metabolismo , Receptores de Calcitonina/metabolismo , Receptor 1 de Factores de Crecimiento Endotelial Vascular/metabolismoRESUMEN
Lung inflammation interrupts alveolarization and causes bronchopulmonary dysplasia (BPD). Besides mechanical ventilation and hyperoxia, sepsis contributes to BPD pathogenesis. Adrenomedullin (Adm) is a multifunctional peptide that exerts anti-inflammatory effects in the lungs of adult rodents. Whether Adm mitigates sepsis-induced neonatal lung injury is unknown. The lung phenotype of mice exposed to early postnatal lipopolysaccharide (LPS) was recently shown to be similar to that in human BPD. This model was used to test the hypothesis that Adm-deficient neonatal mice will display increased LPS-induced lung injury than their wild-type (WT) littermates. Adm-deficient mice or their WT littermates were intraperitoneally administered 6 mg/kg of LPS or vehicle daily on postnatal days (PNDs) 3 to 5. The lungs were harvested at several time points to quantify inflammation, alveolarization, and vascularization. The extent of LPS-induced lung inflammation in Adm-deficient mice was 1.6-fold to 10-fold higher than their WT littermates. Strikingly, Adm deficiency induced STAT1 activation and potentiated STAT3 activation in LPS-exposed lungs. The severity of LPS-induced interruption of lung development was also greater in Adm-deficient mice at PND7. At PND14, LPS-exposed WT littermates displayed substantial improvement in lung development, whereas LPS-exposed Adm-deficient mice continued to have decreased lung development. These data indicate that Adm is necessary to decrease lung inflammation and injury and promote repair of the injured lungs in LPS-exposed neonatal mice.
Asunto(s)
Adrenomedulina/fisiología , Displasia Broncopulmonar/genética , Adrenomedulina/genética , Animales , Animales Recién Nacidos , Displasia Broncopulmonar/inducido químicamente , Displasia Broncopulmonar/patología , Modelos Animales de Enfermedad , Femenino , Dosificación de Gen/fisiología , Lipopolisacáridos , Ratones , Ratones de la Cepa 129 , Ratones Endogámicos C57BL , Ratones Transgénicos , EmbarazoRESUMEN
Agonist bias occurs when different ligands produce distinct signalling outputs when acting at the same receptor. However, its physiological relevance is not always clear. Using primary human cells and gene editing techniques, we demonstrate endogenous agonist bias with physiological consequences for the calcitonin receptor-like receptor, CLR. By switching the receptor-activity modifying protein (RAMP) associated with CLR we can "re-route" the physiological pathways activated by endogenous agonists calcitonin gene-related peptide (CGRP), adrenomedullin (AM) and adrenomedullin 2 (AM2). AM2 promotes calcium-mediated nitric oxide signalling whereas CGRP and AM show pro-proliferative effects in cardiovascular cells, thus providing a rationale for the expression of the three peptides. CLR-based agonist bias occurs naturally in human cells and has a fundamental purpose for its existence. We anticipate this will be a starting point for more studies into RAMP function in native environments and their importance in endogenous GPCR signalling.
Asunto(s)
Adrenomedulina/fisiología , Péptido Relacionado con Gen de Calcitonina/fisiología , Hormonas Peptídicas/fisiología , Receptores Acoplados a Proteínas G/agonistas , Proteína Similar al Receptor de Calcitonina/fisiología , Células Cultivadas , AMP Cíclico/metabolismo , Células Endoteliales/fisiología , Quinasas MAP Reguladas por Señal Extracelular/metabolismo , Humanos , Receptores de Adrenomedulina/agonistas , Receptores de Adrenomedulina/análisis , Receptores de Péptido Relacionado con el Gen de Calcitonina/fisiologíaRESUMEN
Adrenomedullin (AM) is a peptide hormone with multiple physiological functions, which are regulated by its receptor activity-modifying proteins, RAMP2 and RAMP3. We previously reported that AM or RAMP2 knockout (KO) (AM-/-, RAMP2-/-) is embryonically lethal in mice, whereas RAMP3-/- mice are apparently normal. AM, RAMP2, and RAMP3 are all highly expressed in the heart; however, their functions there are not fully understood. Here, we analyzed the pathophysiological functions of the AM-RAMP2 and AM-RAMP3 systems in hearts subjected to cardiovascular stress. Cardiomyocyte-specific RAMP2-/- (C-RAMP2-/-) and RAMP3-/- showed no apparent heart failure at base line. After 1 week of transverse aortic constriction (TAC), however, C-RAMP2-/- exhibited significant cardiac hypertrophy, decreased ejection fraction, and increased fibrosis compared with wild-type mice. Both dP/dtmax and dP/dtmin were significantly reduced in C-RAMP2-/-, indicating reduced ventricular contractility and relaxation. Exposing C-RAMP2-/- cardiomyocytes to isoproterenol enhanced their hypertrophy and oxidative stress compared with wild-type cells. C-RAMP2-/- cardiomyocytes also contained fewer viable mitochondria and showed reduced mitochondrial membrane potential and respiratory capacity. RAMP3-/- also showed reduced systolic function and enhanced fibrosis after TAC, but those only became apparent after 4 weeks. A reduction in cardiac lymphatic vessels was the characteristic feature in RAMP3-/-. These observations indicate the AM-RAMP2 system is necessary for early adaptation to cardiovascular stress through regulation of cardiac mitochondria. AM-RAMP3 is necessary for later adaptation through regulation of lymphatic vessels. The AM-RAMP2 and AM-RAMP3 systems thus play separate critical roles in the maintenance of cardiovascular homeostasis against cardiovascular stress.
Asunto(s)
Adrenomedulina/fisiología , Sistema Cardiovascular/fisiopatología , Proteínas Modificadoras de la Actividad de Receptores/fisiología , Estrés Fisiológico/fisiología , Adrenomedulina/metabolismo , Animales , Animales Recién Nacidos , Cardiomegalia/genética , Cardiomegalia/metabolismo , Cardiomegalia/patología , Cardiomegalia/fisiopatología , Sistema Cardiovascular/metabolismo , Sistema Cardiovascular/patología , Células Cultivadas , Constricción Patológica , Estenosis Coronaria/genética , Estenosis Coronaria/metabolismo , Estenosis Coronaria/patología , Estenosis Coronaria/fisiopatología , Hemodinámica/genética , Homeostasis/genética , Ratones , Ratones Noqueados , Miocitos Cardíacos/patología , Miocitos Cardíacos/fisiología , Estrés Oxidativo/genética , Proteína 2 Modificadora de la Actividad de Receptores/genética , Proteína 2 Modificadora de la Actividad de Receptores/metabolismo , Proteína 2 Modificadora de la Actividad de Receptores/fisiología , Proteína 3 Modificadora de la Actividad de Receptores/genética , Proteína 3 Modificadora de la Actividad de Receptores/metabolismo , Proteína 3 Modificadora de la Actividad de Receptores/fisiología , Proteínas Modificadoras de la Actividad de Receptores/genética , Proteínas Modificadoras de la Actividad de Receptores/metabolismo , Transducción de Señal/genética , Transducción de Señal/fisiologíaRESUMEN
Adrenomedullin (AM) and proadrenomedullin N-terminal 20 peptide (PAMP) are small peptides derived from a common precursor, pre-proadrenomedullin. Although AM and PAMP share hypotensive effects in the cardiovascular system, the peptides also exert diverse and distinct effects on endocrine physiology, innate immunity, cytoskeletal biology and receptor signaling pathways. Tremendous knowledge has been gleaned from the study of several genetic animal models of AM deletion or overexpression, some of which also simultaneously delete the coding region for PAMP peptide. However, deletion of PAMP without concurrent deletion of AM in an animal model is not currently available for the study of PAMP function. Here, we present the generation of AdmΔPAMP/ΔPAMP and AdmΔPAMP/- mice, which lack the coding sequence for PAMP while preserving the coding sequence for AM. AdmΔPAMP/ΔPAMP mice survive to adulthood without any obvious abnormalities and are fertile, though AdmΔPAMP/- females have small litters. Interestingly, these animals express lower levels of Adm mRNA and AM peptide than wild type animals, but these levels are still compatible with survival. Importantly, despite reduced levels, the spatiotemporal expression of AM peptide within the hearts of AdmΔPAMP/- mice remains similar to wild type animals. AdmΔPAMP/ΔPAMP mice are now a publicly available tool for future investigations of PAMP function.
Asunto(s)
Adrenomedulina/genética , Modelos Animales , Precursores de Proteínas/genética , Eliminación de Secuencia , Adrenomedulina/fisiología , Animales , Femenino , Regulación de la Expresión Génica , Ratones , Ratones Noqueados , Miocardio/metabolismo , Fragmentos de Péptidos/genética , Fragmentos de Péptidos/fisiología , Precursores de Proteínas/fisiología , Análisis de SupervivenciaRESUMEN
This study investigated the effect of adrenomedullin (AM) on mechanical pain sensitivity and its possible mechanisms. Intrathecal injection of AM receptor agonist AM1-50 (20⯵g) once per day briefly reduced mechanical pain threshold on days 1 and 2 but induced prolonged mechanical allodynia on day 3. However, AM1-50 did not change mechanical pain sensation when the AM receptor antagonist AM22-52 (20⯵g) was intrathecally co-administered. Daily administration of AM1-50 (20⯵g) for 3â¯days increased expression of phosphorylated extracellular signal-regulated protein kinase (pERK) and neuronal nitric oxide synthase (nNOS) in the spinal dorsal horn. The AM-induced increase in pERK and nNOS was inhibited by the co-administration of AM22-52. The chronic administration of AM1-50 also increased expression of microglial maker Iba1 and astrocytic marker GFAP (glial fibrillary acidic protein) in the spinal dorsal horn in an AM22-52-sensitive manner. Furthermore, the application of AM1-50 (10â¯nM, 3â¯h) to dorsal root ganglion (DRG) explant cultures induced an increase in the expression of transient receptor potential vanilloid 1 (TRPV1). The treatment with AM1-50 did not change TRPV1 expression in DRG in the presence of AM22-52 (2⯵M). These results suggest that the increased AM bioactivity induced mechanical allodynia and may contribute to the mechanical pain hypersensitivity under pathological conditions. The mechanisms may involve the activation of ERK signaling pathway and spinal glia as well as the recruitment of nNOS and TRPV1 in the spinal dorsal horn or DRG. The present study indicates that inhibition of the activation AM receptor might provide a fruitful strategy to relieving chronic pain.
Asunto(s)
Adrenomedulina/fisiología , Ganglios Espinales/metabolismo , Hiperalgesia/fisiopatología , Médula Espinal/metabolismo , Adrenomedulina/administración & dosificación , Adrenomedulina/agonistas , Adrenomedulina/antagonistas & inhibidores , Adrenomedulina/farmacología , Animales , Proteínas de Unión al Calcio/biosíntesis , Células Cultivadas , Interacciones Farmacológicas , Quinasas MAP Reguladas por Señal Extracelular/biosíntesis , Proteína Ácida Fibrilar de la Glía/biosíntesis , Hiperalgesia/metabolismo , Inyecciones Espinales , Masculino , Proteínas de Microfilamentos/biosíntesis , Óxido Nítrico Sintasa de Tipo I/biosíntesis , Dimensión del Dolor/efectos de los fármacos , Fragmentos de Péptidos/administración & dosificación , Fragmentos de Péptidos/farmacología , Fosforilación/efectos de los fármacos , Ratas , Asta Dorsal de la Médula Espinal/metabolismo , Canales Catiónicos TRPV/biosíntesisRESUMEN
Unidirectional flow of oviductal fluid from the ovarian to uterine side of the ampulla plays a significant role in successful pregnancy, and is produced by ciliary beating. Various systems regulate ciliary beating, such as paracrine, autocrine, and endocrine. We hypothesized that Adrenomedullin (ADM)-a peptide hormone that acts via its receptors, which are complexes of Calcitonin receptor-like receptor (CRLR) and Receptor activity-modifying protein (RAMP) 2 or 3 - promotes oviductal fluid flow in the ampulla of bovine oviducts. First, we examined the expression of ADM, CRLR, RAMP2, and RAMP3 mRNAs in isolated epithelial cells throughout the estrous cycle, and the localization of ADM receptor protein constituents in the ampulla. RAMP2 expression was significantly higher in the follicular phase. Furthermore, RAMP2 protein was detected only in ciliated cells, whereas CRLR and RAMP3 were detected in all epithelial cells. The effects of ADM and an ADM antagonist on fluid-flow speed were examined using microbeads in ampullary tissue. ADM antagonist decreased bead transport speed, and this decrease was reversed by ADM. In addition, ADM recovered the bead transport speed that decreased in the absence of calcium. Overall, our results suggest that ADM contributes to the regulation of oviductal fluid flow in ampulla.
Asunto(s)
Adrenomedulina/fisiología , Cilios/fisiología , Oviductos/citología , Oviductos/fisiología , Animales , Calcio/metabolismo , Bovinos , Femenino , Modelos Biológicos , Proteínas Modificadoras de la Actividad de Receptores/metabolismoRESUMEN
Neointimal hyperplasia is the primary lesion underlying atherosclerosis and restenosis after coronary intervention. We previously described the essential angiogenic function of the adrenomedullin (AM)-receptor activity-modifying protein (RAMP) 2 system. In the present study, we assessed the vasoprotective actions of the endogenous AM-RAMP2 system using a wire-induced vascular injury model. We found that neointima formation and vascular smooth muscle cell proliferation were enhanced in RAMP2+/- male mice. The injured vessels from RAMP2+/- mice showed greater macrophage infiltration, inflammatory cytokine expression, and oxidative stress than vessels from wild-type mice and less re-endothelialization. After endothelial cell-specific RAMP2 deletion in drug-inducible endothelial cell-specific RAMP2-/- (DI-E-RAMP2-/-) male mice, we observed markedly greater neointima formation than in control mice. In addition, neointima formation after vessel injury was enhanced in mice receiving bone marrow transplants from RAMP2+/- or DI-E-RAMP2-/- mice, indicating that bone marrow-derived cells contributed to the enhanced neointima formation. Finally, we found that the AM-RAMP2 system augmented proliferation and migration of endothelial progenitor cells. These results demonstrate that the AM-RAMP2 system exerts crucial vasoprotective effects after vascular injury and could be a therapeutic target for the treatment of vascular diseases.
Asunto(s)
Adrenomedulina/fisiología , Citoprotección/genética , Células Endoteliales/fisiología , Proteína 2 Modificadora de la Actividad de Receptores/fisiología , Lesiones del Sistema Vascular/prevención & control , Adrenomedulina/genética , Animales , Células Cultivadas , Arteria Femoral/lesiones , Arteria Femoral/metabolismo , Arteria Femoral/patología , Humanos , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Neointima/genética , Neointima/metabolismo , Neointima/patología , Proteína 2 Modificadora de la Actividad de Receptores/genética , Transducción de Señal/genética , Lesiones del Sistema Vascular/genéticaRESUMEN
BACKGROUND: Renal denervation has been proposed as a therapeutic option in patients with resistant hypertension. Circulating blood borne biomarkers might be helpful to identify individuals responding to RDN therapy. MR-proADM is a strong prognostic marker in patients with cardiovascular disease. The aim of this multicenter study was to evaluate the effect of RDN on MR-proADM concentrations. METHODS AND RESULTS: We measured MR-proADM, BNP, and MR-proANP in 110 patients before and after RDN in a multicenter setting. All patients were followed up after 1 and 6 months by office and ambulatory blood pressure (BP) measurements. The mean office BP decreased from 165/89 to 152/87 mmHg 6 months after RDN (systolic: p < 0.001; diastolic: ns), the responder-rate was 74%. Intriguingly MR-proADM concentrations increased from 0.66 to 0.69 nmol/L (p < 0.001) and were significantly associated with reduction of systolic office BP after 6 months in multivariate analyses (coefficient -0.0018, p < 0.001). In therapy-responders MR-proADM concentrations showed a significantly higher increase over time (coefficient 0.0105, p < 0.05), as compared to non-responders. There were no significant differences in BP change for individuals with low and high baseline MR-proADM (BP-Delta low MR-proADM -23/-4 mmHg vs. high MR-proADM -24/-5 mmHg). The natriuretic biomarkers BNP and MR-proANP did not change significantly after 6 months. Biomarkers at baseline were not able to predict for therapy-responder. CONCLUSION: In patients undergoing RDN, baseline measurements of various biomarkers had no prognostic use for therapy success in this short time follow-up period in a multicenter approach. Intriguingly, MR-proADM showed a significant association with BP reduction after 6 months.
Asunto(s)
Adrenomedulina/fisiología , Desnervación , Hipertensión/terapia , Riñón/inervación , Precursores de Proteínas/fisiología , Anciano , Biomarcadores/sangre , Presión Sanguínea , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Péptido Natriurético Encefálico/sangre , Pronóstico , Factores de Tiempo , Resultado del TratamientoRESUMEN
La adrenomedulina (AM) es un péptido involucrado en la regulación cardiovascular. En el cerebelo, la densidad de los receptores de la AM se encuentra alterada durante la hipertensión, sugiriendo un posible papel del sistema adrenomedulinérgico cerebelar en la regulación de la presión arterial (PA). El objetivo del presente estudio fue evaluar el efecto funcional in vivo de la AM durante el estrés agudo, mediante la administración in situ de AM en el vermis cerebelar de la rata. Se emplearon ratas adultas normotensas Wistar Kyoto (WKY) y Sprague Dawley (SD) y ratas espontáneamente hipertensas (SHR) las cuales fueron anestesiadas y posteriormente canuladas en el vermis cerebelar. El estrés se indujo mediante el uso del estímulo eléctrico plantar (EEP). Los animales fueron divididos en grupos que recibieron AM (0,2 o 200 pmol/5μL) o vehículo (solución fisiológica, 5μL). La PA se determinó antes del experimento y después de la administración del tratamiento respectivo, seguida de la aplicación del EEP (100 V, 5 Hz, 10 mseg, durante 4 minutos). La PA se determinó mediante pletismografía digital no invasiva. Los resultados demuestran que la microinyección de AM (0,2 y 200 pmol) in situ en el vermis cerebeloso en ratas SD, WKY y SHR disminuye significativamente la respuesta presora frente al estrés inducido por el EEP, lo que sugiere que la acción hipotensora está mediada a través de la regulación del eflujo simpático. Estos hallazgos demuestran la participación de la AM cerebelosa en la regulación de la respuesta cardiovascu lar frente al estrés.
Adrenomedullin (AM) is a peptide involved in cardiovascular regulation. In the cerebellum, the density of AM receptors is altered during hypertension, suggesting a pos sible role of cerebellar adrenomedulinergic system in the regulation of blood pressure (BP). The aim of this study was to evaluate the functional role of AM during acute stress, by in situ administration of AM into the cerebellar vermis in rats. Adult normotensive Wistar Kyoto (WKY) and Sprague Dawley (SD) rats and spontaneously hypertensive rats (SHR), were anes thetized and their cerebellar vermis cannulated. Footshock was used as stressor. Animals were divided into groups that received either AM (0.2 and 200 pmol/5μL) or vehicle (physiological saline, 5μL). The BP was determined, using noninvasive digital plethysmography, before and after treatment, followed by footshock (100V, 5 Hz, 10 msec, for 4 minutes). The results show that microinjection of AM (0.2 and 200 pmol) in situ into the cerebellar vermis in SD, WKY and SHR rats, significantly decreased the pressor response induced by footshock stress, sugges ting that the hypotensive action is mediated through regulation of sympathetic outflow. Taken together, our results demonstrate a role of cerebellar AM in the regulation of cardiovascular response to stress.
Asunto(s)
Animales , Masculino , Estrés Fisiológico/fisiología , Cerebelo/fisiología , Adrenomedulina/fisiología , Ratas Wistar , Ratas Sprague-DawleyRESUMEN
INTRODUCTION: Adrenomedullin (ADM) is highly expressed in dental tissues at the critical developmental time points during tooth development. However, its role in pulp repair and pulp injury is still unknown. The study aimed to investigate the mechanisms by which ADM affects the proliferation and apoptosis of human dental pulp stem cells (DPSCs). METHODS: Fifty-four freshly extracted wisdom teeth were obtained from 27 patients with caries and 27 without. Enzyme-linked immunosorbent assay and immunohistochemistry were used to examine the expression levels of ADM in caries and normal pulp tissues. Human primary DPSCs from the third passage were incubated with ADM (10(-8) mol/L) for 24 hours; the cell cycle and apoptosis were investigated by flow cytomery, and protein expression was investigated using Western blot analysis. RESULTS: The levels of ADM in caries pulp tissues were significantly higher than those in normal pulp tissues. Incubation with ADM enhanced the percentage of G2/S/M phase DPSCs (P < .01) by the addition of a JNK/c-Jun inhibitor. Incubation with ADM reduced DPSC apoptosis by the addition of the Src/glycogen synthase kinase-3 inhibitor. ADM also ameliorated CoCl2-induced apoptosis and caspase-3 expression. CONCLUSIONS: ADM enhances the proliferation of DPSCs through activation of the JNK/c-Jun signaling pathway and inhibits apoptosis of DPSCs through activation of the Src/glycogen synthase kinase-3 signaling pathway.
Asunto(s)
Adrenomedulina/fisiología , Pulpa Dental/citología , Células Madre/fisiología , Adolescente , Adulto , Apoptosis/fisiología , Western Blotting , Proliferación Celular/fisiología , Pulpa Dental/fisiología , Ensayo de Inmunoadsorción Enzimática , Citometría de Flujo , Glucógeno Sintasa Quinasa 3/fisiología , Humanos , Sistema de Señalización de MAP Quinasas/fisiología , Proteínas Proto-Oncogénicas pp60(c-src)/fisiología , Transducción de Señal/fisiología , Células Madre/citología , Adulto JovenRESUMEN
Adrenomedullin (AM) is a potent vasodilatory 52-aminoacid peptide hormone, ubiquitous with multiple physiological effects which contribute to homeostatic responses. Significantly, it is distributed in the adrenal gland, lung, cardiovascular and renal system. The biological effects of AM are directly mediated by specific receptors as heterodimers composed of the calcitonin-receptor-like receptor (CLR) and one of two receptor activity modifying proteins (RAMP2 or RAMP3). The CLR/RAMP2 (AM1 receptor) is more highly AM-specific than The CLR/RAMP3 (AM2 receptor). Plasma levels of AM are elevated proportionately to the increase in blood pressure and degree of renal damage in patients with hypertension; likewise, these levels are correlated with the degree ofheart and arterial hypertrophy. AM has renal vasodilatory, natriuretic and diuretic actions; increased glomerular filtration rate and renal blood flow. AM inhibits proliferation and reactive oxygen species generation in mesangial cells; also inhibits aldosterone secretion in the zona glomerulosa and endothelin-1 in vascular smooth muscle cells. Therefore, it is proposed as a new marker in various diseases, especially chronic renal failure. This disease presents compensatory hypertrophy of the glomeruli and mesangial proliferation, administration of AM reduces the levels of proteinuria, suggesting that AM has an important modulator role in blood pressure and could be a therapeutic option for chronic renal failure.
Asunto(s)
Adrenomedulina/fisiología , Riñón/fisiología , Adrenomedulina/uso terapéutico , Humanos , Riñón/fisiopatología , Fallo Renal Crónico/tratamiento farmacológicoRESUMEN
Adrenomedullin (AM) and proadrenomedullin N-terminal 20 peptide (PAMP) are 2 biologically active peptides produced by the same gene, ADM, with ubiquitous distribution and many physiological functions. Adrenomedullin is composed of 52 amino acids, has an internal molecular ring composed by 6 amino acids and a disulfide bond, and shares structural similarities with calcitonin gene-related peptide, amylin, and intermedin. The AM receptor consists of a 7-transmembrane domain protein called calcitonin receptor-like receptor in combination with a single transmembrane domain protein known as receptor activity-modifying protein. Using morphologic techniques, it has been shown that AM and PAMP are expressed throughout the gastrointestinal tract, being specially abundant in the neuroendocrine cells of the gastrointestinal mucosa; in the enterochromaffin-like and chief cells of the gastric fundus; and in the submucosa of the duodenum, ileum, and colon. This wide distribution in the gastrointestinal tract suggests that AM and PAMP may act as gut hormones regulating many physiological and pathologic conditions. To date, it has been proven that AM and PAMP act as autocrine/paracrine growth factors in the gastrointestinal epithelium, play key roles in the protection of gastric mucosa from various kinds of injury, and accelerate healing in diseases such as gastric ulcer and inflammatory bowel diseases. In addition, both peptides are potent inhibitors of gastric acid secretion and gastric emptying; they regulate the active transport of sugars in the intestine, regulate water and ion transport in the colon, modulate colonic bowel movements and small-intestine motility, improve endothelial barrier function, and stabilize circulatory function during gastrointestinal inflammation. Furthermore, AM and PAMP are antimicrobial peptides, and they contribute to the mucosal host defense system by regulating gut microbiota. To get a formal demonstration of the effects that endogenous AM and PAMP may have in gut microbiota, we developed an inducible knockout of the ADM gene. Using this model, we have shown, for the first time, that lack of AM/PAMP leads to changes in gut microbiota composition in mice. Further studies are needed to investigate whether this lack of AM/PAMP may have an impact in the development and/or progression of intestinal diseases through their effect on microbiota composition.
Asunto(s)
Adrenomedulina/fisiología , Intestinos/fisiología , Animales , Regulación de la Expresión Génica , Receptores de Adrenomedulina/metabolismo , Transducción de Señal/fisiologíaRESUMEN
La adrenomedulina (ADM), péptido vasodilatador de 52 aminoácidos, ubícuo, posee múltiples efectos fisiológicos que contribuyen a respuestas homeostáticas. Se encuentra en concentraciones importantes en la glándula suprarrenal, el pulmón, el sistema cardiovascular y el renal. Ejerce acciones biológicas a través de sus receptores AM1 y AM2, heterodímeros constituidos por el receptor semejante al receptor de calcitonina (CLR) y proteínas modificadoras de la actividad del receptor (RAMPs), CLR/RAMP2 y CLR/RAMP3, respectivamente. La principal vía de señalización es la adenilato ciclasa/AMPc en patologías cardiovasculares y renales, así como en la sepsis. Los niveles plasmáticos de ADM se elevan proporcionalmente con el incremento de la presión sanguínea y con el grado de daño renal, en pacientes con hipertensión arterial; así mismo, dichos niveles se correlacionan con el grado de hipertrofia cardíaca y arterial. La ADM tiene efectos renales, tubulares, ya que tiene acción diurética y natriurética; posee efectos vasodilatadores que producen aumento de la tasa de filtración glomerular y del flujo sanguíneo renal. Este péptido inhibe la proliferación y la generación de radicales libres en células mesangiales; actúa inhibiendo la secreción de aldosterona en la zona glomerulosa y de endotelina-1 en células musculares lisas vasculares. Se ha propuesto como marcador de riesgo en diversas patologías, especialmente en la insuficiencia renal crónica; en esta patología, que cursa con hipertrofia compensadora de los glomérulos y proliferación del mesangio, la administración de ADM disminuye los niveles de proteinuria, lo que sugiere que además de un importante rol modulador en la presión arterial, pudiera ser una opción terapéutica para la insuficiencia renal crónica.
Adrenomedullin (AM) is a potent vasodilatory 52-aminoacid peptide hormone, ubiquitous with multiple physiological effects which contribute to homeostatic responses. Significantly, it is distributed in the adrenal gland, lung, cardiovascular and renal system. The biological effects of AM are directly mediated by specific receptors as heterodimers composed of the calcitonin-receptor-like receptor (CLR) and one of two receptor activity modifying proteins (RAMP2 or RAMP3). The CLR/RAMP2 (AM1 receptor) is more highly AM-specific than The CLR/RAMP3 (AM2 receptor). Plasma levels of AM are elevated proportionately to the increase in blood pressure and degree of renal damage in patients with hypertension; likewise, these levels are correlated with the degree of heart and arterial hypertrophy. AM has renal vasodilatory, natriuretic and diuretic actions; increased glomerular filtration rate and renal blood flow. AM inhibits proliferation and reactive oxygen species generation in mesangial cells; also inhibits aldosterone secretion in the zona glomerulosa and endothelin-1 in vascular smooth muscle cells. Therefore, it is proposed as a new marker in various diseases, especially chronic renal failure. This disease presents compensatory hypertrophy of the glomeruli and mesangial proliferation, administration of AM reduces the levels of proteinuria, suggesting that AM has an important modulator role in blood pressure and could be a therapeutic option for chronic renal failure.
Asunto(s)
Humanos , Adrenomedulina/fisiología , Riñón/fisiología , Adrenomedulina/uso terapéutico , Riñón/fisiopatología , Fallo Renal Crónico/tratamiento farmacológicoRESUMEN
Adrenomedullin (AM) is a peptide involved in cardiovascular regulation. In the cerebellum, the density of AM receptors is altered during hypertension, suggesting a possible role of cerebellar adrenomedulinergic system in the regulation of blood pressure (BP). The aim of this study was to evaluate the functional role of AM during acute stress, by in situ administration of AM into the cerebellar vermis in rats. Adult normotensive Wistar Kyoto (WKY) and Sprague Dawley (SD) rats and spontaneously hypertensive rats (SHR), were anesthetized and later, their cerebellar vermis cannulated. Footshock was used as stressor. Animals were divided into groups that received either AM (0.2 and 200 pmol/5µL) or vehicle (physiological saline, 5µL). The BP was determined, using noninvasive digital plethysmography, before and after treatment, followed by the application of footshock (100V, 5 Hz, 10 msec, for 4 minutes). The results show that microinjection of AM (0.2 and 200 pmol) in situ into the cerebellar vermis in SD, WKY and SHR rats, significantly decreased the pressor response induced by footshock stress, suggesting that the hypotensive action is mediated through regulation of sympathetic outflow. Taken together, our results demonstrate a role of cerebellar AM in the regulation of cardiovascular response to stress.
Asunto(s)
Adrenomedulina/fisiología , Cerebelo/fisiología , Estrés Fisiológico/fisiología , Animales , Masculino , Ratas Sprague-Dawley , Ratas WistarRESUMEN
Adrenomedullin (AMD), proadrenomedullin N-terminal 20 peptide (PAMP) and calcitonin gene-related peptide (CGRP) were studied for chemotaxis, chemotactic selection and G-actin/F-actin transition in Tetrahymena. The aim of the experiments was to study the effects of two different peptides encoded by the same gene compared to a peptide related to one of the two, but encoded by a different gene, at a low level of phylogeny. The positive, chemotactic effect of ADM and the strong negative, chemorepellent effect of PAMP suggest that in Tetrahymena, the two peptides elicit their chemotactic effects via different signalling mechanisms. The complexity of swimming behaviour modulated by the three peptides underlines that chemotaxis, chemokinesis and some characteristics of migratory behaviour (velocity, tortuosity) are working as a sub-population level complex functional unit. Chemotactic responsiveness to ADM and CGRP is short-term, in contrast to PAMP, which as a chemorepellent ligand, has the ability to select sub-populations with negative chemotactic responsiveness. The different effects of ADM and PAMP on the polymerization of actin networks show that the microtubular structure of cilia is more essential to chemotactic response than are transitions of the actin network. The results draw attention to the characteristic effects of vasoactive peptides at this low level of phylogeny.
Asunto(s)
Adrenomedulina/fisiología , Péptido Relacionado con Gen de Calcitonina/fisiología , Quimiotaxis/fisiología , Tetrahymena pyriformis/fisiología , Tetrahymena pyriformis/metabolismoRESUMEN
Adrenomedullin (AM) and their receptor components, calcitonin-receptor-like receptor (CRLR) and receptor activity-modifying protein (RAMP1, RMP2 and RAMP3) are widely expressed in the central nervous system, including cerebellum. We have shown that AM binding sites are altered in cerebellum during hypertension, suggesting a role for cerebellar adrenomedullinergic system in blood pressure regulation. To further evaluate the role of AM in cerebellum, we assessed the expression of AM, RAMP1, RAMP2, RAMP3 and CRLR in the cerebellar vermis of 8 and 16week old spontaneously hypertensive (SHR) and normotensive Wistar Kyoto (WKY) rats. In addition, the effect of microinjection of AM into rat cerebellar vermis on arterial blood pressure (BP) was determined. Animals were sacrificed by decapitation and cerebellar vermis was dissected for quantification of AM, CRLR, RAMP1, RAMP2 and RAMP3 expression using western blot analysis. Another group of male, 16week old SHR and WKY rats was anesthetized, and a cannula was implanted in the cerebellar vermis. Following recovery AM (0.02 to 200pmol/5µL) or vehicle was injected into cerebellar vermis. BP was determined, before and after treatments, by non-invasive plethysmography. In addition, to establish the receptor subtype involved in AM action in vivo, animals received microinjections of AM22-52 (200pmol/5µL), an AM1 receptor antagonist, or the CGRP1 receptor antagonist, CGRP8-37 (200pmol/5µL) into the cerebellar vermis, administered simultaneously with AM or vehicle microinjection. Cannulation was verified post mortem with the in situ injection of a dye solution. Our findings demonstrated that the expression of CRLR, RAMP1 and RAMP3 was higher in cerebellum of SHR rats, while AM and RAMP2 expression was lower than those of WKY rats, both in 8 and 16week old rats. In vivo microinjection of AM into the cerebellar vermis caused a profound, dose dependent, hypotensive effect in SHR but not in normotensive WKY rats. Coinjections of a putative AM receptor antagonist, AM22-52 abolished the decreases in mean arterial pressure (MAP) evoked by AM, showing that AM acts through its AM1 receptor in the vermis to reduce MAP. These findings demonstrate a dysregulation of cerebellar AM-system during hypertension, and suggest that cerebellar AM plays an important role in the regulation of BP. Likewise; they constitute a novel mechanism of BP control which has not been described so far.
Asunto(s)
Adrenomedulina/fisiología , Presión Sanguínea , Vermis Cerebeloso/fisiología , Hipertensión/metabolismo , Hipertensión/fisiopatología , Proteínas Modificadoras de la Actividad de Receptores/metabolismo , Adrenomedulina/administración & dosificación , Adrenomedulina/metabolismo , Animales , Presión Arterial/efectos de los fármacos , Péptido Relacionado con Gen de Calcitonina/administración & dosificación , Proteína Similar al Receptor de Calcitonina/metabolismo , Vermis Cerebeloso/efectos de los fármacos , Vermis Cerebeloso/metabolismo , Masculino , Fragmentos de Péptidos/administración & dosificación , Ratas , Ratas Endogámicas SHR , Ratas Endogámicas WKY , Proteína 1 Modificadora de la Actividad de Receptores/metabolismo , Proteína 2 Modificadora de la Actividad de Receptores/metabolismo , Proteína 3 Modificadora de la Actividad de Receptores/metabolismoRESUMEN
Cerebral blood flow autoregulation (CA) shifts to higher blood pressures in chronic hypertensive patients, which increases their risk for brain damage. Although cerebral vascular smooth muscle cells express the potent vasodilatatory peptides calcitonin gene-related peptide (CGRP) and adrenomedullin (AM) and their receptors (calcitonin receptor-like receptor (Calclr), receptor-modifying proteins (RAMP) 1 and 2), their contribution to CA during chronic hypertension is poorly understood. Here we report that chronic (10 weeks) hypertensive (one-kidney-one-clip-method) mice overexpressing the Calclr in smooth muscle cells (CLR-tg), which increases the natural sensitivity of the brain vasculature to CGRP and AM show significantly better blood pressure drop-induced cerebrovascular reactivity than wt controls. Compared to sham mice, this was paralleled by increased cerebral CGRP-binding sites (receptor autoradiography), significantly in CLR-tg but not wt mice. AM-binding sites remained unchanged. Whereas hypertension did not alter RAMP-1 expression (droplet digital (dd) PCR) in either mouse line, RAMP-2 expression dropped significantly in both mouse lines by about 65%. Moreover, in wt only Calclr expression was reduced by about 70% parallel to an increase of smooth muscle actin (Acta2) expression. Thus, chronic hypertension induces a stoichiometric shift between CGRP and AM receptors in favor of the CGRP receptor. However, the parallel reduction of Calclr expression observed in wt mice but not CLR-tg mice appears to be a key mechanism in chronic hypertension impairing cerebrovascular reactivity.
Asunto(s)
Circulación Cerebrovascular/fisiología , Hipertensión/fisiopatología , Receptores de Péptido Relacionado con el Gen de Calcitonina/fisiología , Adrenomedulina/fisiología , Animales , Sitios de Unión , Encéfalo/fisiopatología , Proteína Similar al Receptor de Calcitonina/genética , Proteína Similar al Receptor de Calcitonina/fisiología , Circulación Cerebrovascular/genética , Femenino , Hipertensión/genética , Ratones , Ratones Endogámicos DBA , Ratones Transgénicos , Datos de Secuencia Molecular , Ratas , Proteína 1 Modificadora de la Actividad de Receptores/genética , Proteína 1 Modificadora de la Actividad de Receptores/fisiología , Proteína 2 Modificadora de la Actividad de Receptores/genética , Proteína 2 Modificadora de la Actividad de Receptores/fisiología , Receptores de Péptido Relacionado con el Gen de Calcitonina/genética , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismoRESUMEN
Adrenomedullin (AM) is a regulatory peptide whose involvement in tumour progression is becoming more relevant with recent studies. AM is produced and secreted by the tumour cells but also by numerous stromal cells including macrophages, mast cells, endothelial cells, and vascular smooth muscle cells. Most cancer patients present high levels of circulating AM and in some cases these higher levels correlate with a worst prognosis. In some cases it has been shown that the high AM levels return to normal following surgical removal of the tumour, thus indicating the tumour as the source of this excessive production of AM. Expression of this peptide is a good investment for the tumour cell since AM acts as an autocrine/paracrine growth factor, prevents apoptosis-mediated cell death, increases tumour cell motility and metastasis, induces angiogenesis, and blocks immunosurveillance by inhibiting the immune system. In addition, AM expression gets rapidly activated by hypoxia through a HIF-1α mediated mechanism, thus characterizing AM as a major survival factor for tumour cells. Accordingly, a number of studies have shown that inhibition of this peptide or its receptors results in a significant reduction in tumour progression. In conclusion, AM is a great target for drug development and new drugs interfering with this system are being developed.